GlassScriptPhysician profile
Evelyn D Jankowski
NPI 1083604755
$4,065.22
in general payments reported to CMS, 2019-2025
28 companies · $630 in 2025
The $630 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $71.53 · 2021: $266 · 2022: $957 · 2023: $824 · 2024: $986 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,257 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,256.95 |
| Education | $182.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,236.70 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $646.65 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $352.58 | 2019-2024 | Winlevi |
| Amgen INC. | $328.19 | 2021-2025 | Otezla |
| Janssen Biotech, INC. | $248.76 | 2022-2024 | Tremfya |
| Galderma Laboratories, L.P. | $151.72 | 2019-2024 | Aklief |
| Novartis Pharmaceuticals Corporation | $144.20 | 2019-2024 | |
| Abbvie INC. | $131.38 | 2024-2025 | |
| Pfizer INC. | $124.61 | 2019-2023 | |
| Leo Pharma INC. | $99.56 | 2019-2025 | Anzupgo |
| Dermavant Sciences, INC. | $96.28 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $83.00 | 2023 | |
| Mayne Pharma Commercial LLC | $56.20 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $39.36 | 2022-2023 | Sotyktu |
| Vyne Pharmaceuticals INC. | $37.36 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $32.47 | 2025 | Taltz, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.23 | 2019-2020 | |
| Epi Health, LLC | $29.55 | 2019 | |
| Paratek Pharmaceuticals, INC. | $24.41 | 2024 | Nuzyra |
| Strata Skin Sciences, INC. | $23.09 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $22.91 | 2019 | |
| Dusa Pharmaceuticals, INC. | $21.56 | 2019 | |
| Almirall LLC | $20.41 | 2019 | |
| Organon LLC | $18.84 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $18.50 | 2019 | |
| Arcutis Biotherapeutics, INC. | $17.62 | 2023 | |
| Verrica Pharmaceuticals INC. | $17.00 | 2025 | Ycanth |
| Smith+Nephew, INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Jankowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.